Axsome Therapeutics, Inc. (AXSM) stock
AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
$134.00−1.95 (-1.43%)
Close on Nov 18, 2026Market cap $7.02BP/E –Yield –
Axsome Therapeutics cash
Cash and short-term investments held at the end of each period.
Axsome Therapeutics's cash was $319.85M at Jun 30, 2026. For fiscal 2025 it was $322.93M, up 2.4% from the year before. Over ten years it grew 21.0% a year on average. The highest annual figure on record is $386.19M in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.93M | +2.4% |
| FY2024 | Dec 31, 2024 | $315.35M | -18.3% |
| FY2023 | Dec 31, 2023 | $386.19M | +92.3% |
| FY2022 | Dec 31, 2022 | $200.84M | +132.3% |
| FY2021 | Dec 31, 2021 | $86.47M | -53.0% |
| FY2020 | Dec 31, 2020 | $183.88M | -16.4% |
| FY2019 | Dec 31, 2019 | $219.97M | +1474.7% |
| FY2018 | Dec 31, 2018 | $13.97M | -58.9% |
| FY2017 | Dec 31, 2017 | $34.02M | -7.1% |
| FY2016 | Dec 31, 2016 | $36.62M | -23.8% |
| FY2015 | Dec 31, 2015 | $48.04M | +1735.0% |
| FY2014 | Dec 31, 2014 | $2.62M | +25.4% |
| FY2013 | Dec 31, 2013 | $2.09M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $319.85M | +5.6% |
| Q1 FY2026 | Mar 31, 2026 | $305.11M | +1.4% |
| Q4 FY2025 | Dec 31, 2025 | $322.93M | +2.4% |
| Q3 FY2025 | Sep 30, 2025 | $325.27M | -0.6% |
| Q2 FY2025 | Jun 30, 2025 | $303.02M | -4.0% |
| Q1 FY2025 | Mar 31, 2025 | $300.91M | -9.2% |
| Q4 FY2024 | Dec 31, 2024 | $315.35M | -18.3% |
| Q3 FY2024 | Sep 30, 2024 | $327.34M | -21.4% |
| Q2 FY2024 | Jun 30, 2024 | $315.66M | -27.8% |
| Q1 FY2024 | Mar 31, 2024 | $331.44M | +34.5% |
| Q4 FY2023 | Dec 31, 2023 | $386.19M | +92.3% |
| Q3 FY2023 | Sep 30, 2023 | $416.56M | +83.1% |
| Q2 FY2023 | Jun 30, 2023 | $437.11M | +495.6% |
| Q1 FY2023 | Mar 31, 2023 | $246.52M | +191.0% |
| Q4 FY2022 | Dec 31, 2022 | $200.84M | +132.3% |
| Q3 FY2022 | Sep 30, 2022 | $227.52M | +98.5% |
| Q2 FY2022 | Jun 30, 2022 | $73.39M | -48.0% |
| Q1 FY2022 | Mar 31, 2022 | $84.71M | -48.6% |
| Q4 FY2021 | Dec 31, 2021 | $86.47M | -53.0% |
| Q3 FY2021 | Sep 30, 2021 | $114.62M | -43.4% |
| Q2 FY2021 | Jun 30, 2021 | $141.22M | -25.9% |
| Q1 FY2021 | Mar 31, 2021 | $164.66M | -16.5% |
| Q4 FY2020 | Dec 31, 2020 | $183.88M | -16.4% |
| Q3 FY2020 | Sep 30, 2020 | $202.36M | +363.7% |
| Q2 FY2020 | Jun 30, 2020 | $190.68M | +254.7% |
| Q1 FY2020 | Mar 31, 2020 | $197.31M | +362.9% |
| Q4 FY2019 | Dec 31, 2019 | $219.97M | +1474.7% |
| Q3 FY2019 | Sep 30, 2019 | $43.64M | +186.7% |
| Q2 FY2019 | Jun 30, 2019 | $53.75M | +164.1% |
| Q1 FY2019 | Mar 31, 2019 | $42.62M | +60.0% |
| Q4 FY2018 | Dec 31, 2018 | $13.97M | -58.9% |
| Q3 FY2018 | Sep 30, 2018 | $15.22M | -51.9% |
| Q2 FY2018 | Jun 30, 2018 | $20.35M | -46.4% |
| Q1 FY2018 | Mar 31, 2018 | $26.63M | -40.8% |
| Q4 FY2017 | Dec 31, 2017 | $34.02M | -7.1% |
| Q3 FY2017 | Sep 30, 2017 | $31.67M | -6.5% |
| Q2 FY2017 | Jun 30, 2017 | $37.99M | – |
| Q1 FY2017 | Mar 31, 2017 | $45.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $36.62M | – |
| Q3 FY2016 | Sep 30, 2016 | $33.89M | – |
See a number that looks wrong?